0
0

Ending the Diagnostic Odyssey Act of 2019

10/28/2022, 1:46 AM

Congressional Summary of S 3116

Ending the Diagnostic Odyssey Act of 2019

This bill allows state Medicaid programs to cover whole genome sequencing services for certain individuals.

Specifically, states may cover such services for individuals under the age of 21 (or a lower age, if the state chooses) and for former foster youth under the age of 26 who (1) have been referred or admitted to an intensive care unit or seen by a medical specialist for a suspected genetic or undiagnosed disease, or (2) are suspected by a medical specialist to have a neonatal- or pediatric-onset genetic disease.

The Centers for Medicare & Medicaid Services may award grants to assist states in developing plans to cover such services.

Current Status of Bill S 3116

Bill S 3116 is currently in the status of Bill Introduced since December 19, 2019. Bill S 3116 was introduced during Congress 116 and was introduced to the Senate on December 19, 2019.  Bill S 3116's most recent activity was Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S7211) as of December 19, 2019

Bipartisan Support of Bill S 3116

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
4
Democrat Cosponsors
3
Republican Cosponsors
1
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 3116

Primary Policy Focus

Health

Potential Impact Areas

- Adoption and foster care
- Cell biology and embryology
- Child health
- Emergency medical services and trauma care
- Genetics
- Health care costs and insurance
- Health care coverage and access
- Health care quality
- Health programs administration and funding
- Health technology, devices, supplies
- Hospital care
- Medicaid
- Medical tests and diagnostic methods
- State and local government operations

Alternate Title(s) of Bill S 3116

Ending the Diagnostic Odyssey Act of 2019
Ending the Diagnostic Odyssey Act of 2019
A bill to enable States to better provide access to whole genome sequencing clinical services for certain undiagnosed children under the Medicaid program, and for other purposes.

Comments